This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock
by Zacks Equity Research
Valneva reports positive data from its Phase 3 - VLA1553-321 study of the IXCHIQ vaccine.
Reasons to Retain TNDM Stock in Your Portfolio for Now
by Zacks Equity Research
A robust diabetes market and several strategic developments raise investors' optimism for Tandem Diabetes.
BSX Stock Rises on Positive Data Announcement at the AF Symposium
by Zacks Equity Research
Boston Scientific announces favorable study data for its FARAPULSE PFA system and WATCHMAN FLX device at the AF Symposium 2025.
Strategic Collaborations Aid QGEN Stock Amid Competition
by Zacks Equity Research
QIAGEN invests heavily in research and development to support internal growth, including the menu expansion of its key platforms.
NEOG Stock Gains Following the Launch of Its New MDA2QSAL96 Kit
by Zacks Equity Research
Neogen launches the new Molecular Detection Assay 2 - Quantitative Salmonella (MDA2QSAL96) to deliver consistency and sensitivity with an easy-to-use workflow that saves time and resources.
Align Technology Shares Hurt by Macro Issues, Decline in ASPs
by Zacks Equity Research
ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This resulted in a decline in the company's revenues.
Reasons to Retain Envista Stock in Your Portfolio for Now
by Zacks Equity Research
NVST's strong focus on international market expansion appears promising. Yet, a leveraged balance sheet is worrisome.
HSIC Stock Might Rise Following the Acquisition of Acentus
by Zacks Equity Research
Henry Schein completes the acquisition of Acentus, which expands the former's Home Solution business.
PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU
by Zacks Equity Research
Insulet announces the launch of Omnipod 5 in five more countries in Europe, Italy, Denmark, Finland, Norway and Sweden.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
by Zacks Equity Research
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
TECH Stock Might Rise From the Expansion of Designer Protein Portfolio
by Zacks Equity Research
Bio-Techne launches AI-engineered designer proteins to advance cell therapy and regenerative medicine.
GMED Stock Rides on NuVasive Synergy Benefits Amid Macro Issues
by Zacks Equity Research
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
MYGN Stock Gains Following Collaboration With Hannah Storm
by Zacks Equity Research
Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program ambassador.
Expanding Global Network, Vaccine Sales Support PAHC Stock
by Zacks Equity Research
Phibro Animal Health is focusing on new developments along with incremental registrations and growing volumes of existing vaccine technologies.
BSX Stock Rises Following Bolt Medical Acquisition Deal Announcement
by Zacks Equity Research
Boston Scientific inks a new agreement to acquire Bolt Medical, developer of Bolt IVL, for approximately $443 million.
QGEN Stock Might Rise Following Partnership With Genomics England
by Zacks Equity Research
QIAGEN partners with Genomics England to support the United Kingdom's initiative to sequence the genomes of 100,000 newborns with expert-curated genomic content.
Endoscopy Sales Growth to Support BSX Stock Amid Fierce Competition
by Zacks Equity Research
Boston Scientific successfully continues its expansion of operations across different geographies outside the United States.
HOLX Stock Gains Following the Acquisition of Gynesonics
by Zacks Equity Research
Hologic completes the acquisition of Gynesonics, developer of the Sonata System, for approximately $350 million.
Reasons to Add Penumbra Stock to Your Portfolio Now
by Zacks Equity Research
PEN stays on investors' radars due to its strong Thrombectomy business and international growth plans.
Omnicell Gains 26.2% in a Year: What's Driving the Stock?
by Zacks Equity Research
OMCL's shares rise on the back of its XT Amplify program gaining market traction with its initial offerings. However, the unfavorable macroeconomic scenario is concerning.
EssilorLuxottica to Acquire Pulse Audition: Will the Stock Rise?
by Zacks Equity Research
ESLOY is set to acquire Pulse Audition, an AI-driven tech startup, to strengthen its position in the hearing solution space.
ResMed Gains 37.8% in a Year: What's Driving the Stock?
by Zacks Equity Research
RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is concerning.
Reasons to Retain Phibro Stock in Your Portfolio Now
by Zacks Equity Research
PAHC's prospering Vaccine business sparks optimism for future growth. However, headwinds such as unfavorable foreign exchange might hamper the company's operations.
Reasons to Retain Medtronic Stock in Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about MDT due to its impressive Neuroscience portfolio. Yet, the dull macroeconomic scenario poses a concern to the company's margins.
Here's Why You Should Retain HOLX Stock in Your Portfolio Now
by Zacks Equity Research
Hologic's strength in the Surgical wing instills optimism among investors. Yet, currency impacts raise concerns.